Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
J Thorac Cardiovasc Surg. 2010 Apr;139(4):1033-40. doi: 10.1016/j.jtcvs.2009.05.032. Epub 2009 Jul 25.
We evaluated roles of serotonin 1B and 2A receptors, thromboxane synthase and receptor, and phospholipases A(2) and C in response to cardiopulmonary bypass.
Patients' atrial tissues were harvested before and after cardiopulmonary bypass with cardioplegia (n = 13). Coronary microvessels were assessed for vasoactive response to serotonin with and without inhibitors of serotonin 1B and 2A receptors and phospholipases A(2) and C. Expressions of serotonin receptor messenger RNA were determined with reverse transcriptase polymerase chain reaction. Expressions of serotonin receptors and thromboxane A(2) receptor and synthase proteins were determined with immunoblotting and immunohistochemistry.
Microvessel exposure to serotonin elicited 7.3% +/- 2% relaxation before bypass, changing to contraction of -19.2% +/- 2% after bypass (P <.001). Additions of specific serotonin 1B receptor antagonist and inhibitor of phospholipase A(2) resulted in significantly decreased contraction, -8.6% +/- 1% (P < .001) and 2.8% +/- 3% (P = .001), respectively. Serotonin 1B receptor messenger RNA expression increased 1.82 +/- 0.34-fold after bypass (p = .044); serotonin 2A receptor messenger RNA expression did not change. Serotonin 1B but not 2A receptor protein expression increased after bypass by 1.35 +/- 0.7-fold (P = .0413). Thromboxane synthase and receptor expressions were unchanged after bypass. Serotonin 1B receptor increased mainly in arterial smooth muscle. There were no appreciable differences in arterial expressions of thromboxane synthase or receptor.
Serotonin-induced vascular dysfunction after cardiopulmonary bypass with cardioplegic arrest may be mediated by increased expression of serotonin 1B receptor and subsequent phospholipase A(2) activation in myocardial coronary smooth muscle.
我们评估了 5-羟色胺 1B 和 2A 受体、血栓素合酶和受体以及磷脂酶 A2 和 C 在体外循环中的作用。
在体外循环和心脏停搏时(n = 13)采集患者心房组织。评估冠状微血管对 5-羟色胺的血管活性反应,以及有无 5-羟色胺 1B 和 2A 受体和磷脂酶 A2 和 C 的抑制剂。用逆转录聚合酶链反应确定 5-羟色胺受体信使 RNA 的表达。用免疫印迹和免疫组化法测定 5-羟色胺受体和血栓素 A2 受体和合酶蛋白的表达。
微血管暴露于 5-羟色胺,在体外循环前引起 7.3% +/- 2%的舒张,在体外循环后变为-19.2% +/- 2%的收缩(P <.001)。加入特异性 5-羟色胺 1B 受体拮抗剂和磷脂酶 A2 抑制剂后,收缩明显减少,分别为-8.6% +/- 1%(P <.001)和 2.8% +/- 3%(P =.001)。体外循环后 5-羟色胺 1B 受体信使 RNA 表达增加 1.82 +/- 0.34 倍(p =.044);5-羟色胺 2A 受体信使 RNA 表达不变。体外循环后 5-羟色胺 1B 受体蛋白表达增加 1.35 +/- 0.7 倍(P =.0413)。血栓素合酶和受体表达在体外循环后不变。5-羟色胺 1B 受体主要在动脉平滑肌中增加。动脉血栓素合酶或受体的表达没有明显差异。
心脏停搏体外循环后 5-羟色胺引起的血管功能障碍可能是由于心肌冠状平滑肌中 5-羟色胺 1B 受体表达增加和随后的磷脂酶 A2 激活介导的。